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7Introductory note
Three in-depth reviews of topical interest are published as ‘Selected issues’ in conjunction with the annual report each year. 
These selected issues are based on information provided to the EMCDDA by the EU Member States and candidate countries 
and Norway (participating in the work of the EMCDDA since 2001) as part of the national reporting process.
The three issues selected for 2007 are: 
• Drugs and driving; 
• Drug use and related problems among very young people (under 15 years old);
• Cocaine and crack cocaine: a growing public health issue.
Online versions of the 2007 selected issues (in English) and summaries (in 23 languages) are available at: 
http://issues07.emcdda.europa.eu
The national reports of the Reitox focal points are available on the EMCDDA website 
(http://www.emcdda.europa.eu/?nnodeid=435).
The 2007 Annual report on the state of the drugs problem in Europe is available in 23 languages and may be found at 
http://annualreport.emcdda.europa.eu
8
9Drug use and related problems among very young people 
(under 15 years old)
Introduction
The available information at European level (see 
’Methodology’) suggests that illicit drug use among very 
young people is confined to a small minority who experiment 
with drugs at a very early age. Regular use among the very 
young is rarer still — as is partly reflected in the European 
data on people attending drug treatment. Among those 
who start using substances at a very young age, evidence 
suggests that early experimentation with psychoactive 
substances, including alcohol and tobacco, is associated 
with an increased risk of developing drug problems later 
in life. Regular drug use among the under-15s is most often 
found among a highly problematic group of the population, 
in whom drug use is combined with other concurrent or 
preceding psychological and social disorders and might 
often be a marker of social problems or of an underlying 
neurobehavioural pathway (Clark et al., 2005). 
Responses targeted at substance use by very young people 
usually focus on both licit and illicit substances and, 
in addition to tackling the problems relating to substance 
use, seek to bring about early treatment of concomitant 
psychological or social disorders. This approach is also 
reflected in European and national legislation and strategies. 
Interventions aimed at very young people range from 
universal approaches to early intervention, when substance 
use is already suspected. Drug treatment targeted at 
drug-using young people is rare, but most European countries 
have identified the need for such programmes.
Legal regulations are especially important in protecting 
children and adolescents from drugs and ensuring that they 
have easy access to help and support. Education plays 
a crucial role in this respect, and the responsibility for this 
may be assumed by authorities if it cannot be fulfilled by 
parents. In this selected issue, information from Europe on the 
prevalence and patterns of substance use among very young 
people and on available responses in terms of legislation, 
prevention and treatment is presented. 
Prevalence and patterns of alcohol, 
tobacco and illicit drug use
Estimates of substance use among children under 15 years 
are commonly based on school surveys. While few very 
young people take drugs, and drug dependence by the age 
of 15 is extremely rare, experimental substance use among 
very young people is widely recognised as a predictor of 
future dependence and other drug problems (Gfroerer et 
al., 2002). For example, a large representative survey of 
17-year-olds in France found that two thirds of respondents 
who smoked cannabis for the first time before the age of 
12 were daily cannabis users by the time they were 17, 
whereas those who did not start smoking cannabis until the 
age of 16–17 were mostly occasional smokers (Figure 1). 
While the time elapsed since first use may play a part, 
evidence from adult surveys suggests that first cannabis use 
at a young age is a stronger marker for daily use than the 
duration of time since first use. 
Methodology
Information on substance use and drug-related problems 
among very young people is scarce and is often not 
harmonised at European level. Frequently, national or local 
research on drug use among young people is based on 
different age groups or specially targeted populations. 
The EMCDDA collects data on young people under 
15 years in three epidemiological indicators: the general 
school population indicator; the treatment demand indicator; 
and the drug-related deaths indicator. Information on the 
age at fi rst drug use in the general school student population 
is available from almost all EU Member States for the 
15–16-year-old age group, largely through ESPAD (Hibell 
et al., 2004), and 12 countries report the prevalence of 
psychoactive substance use among school students under the 
age of 15. Prevalence estimates of drug use among under-15s 
are very low, are based on relatively small numbers and, 
therefore, must be viewed with caution. The 2006 Reitox 
national reports included a specifi c analysis of drug treatment 
clients under 15 years in seven volunteer countries, with 
a breakdown by year of age from 10 to 14 years. The 
reference age group is not always restricted to young people 
under the age of 15 (e.g. school information on high-risk 
groups and correlates) to allow comparisons with the situation 
in other age groups.
10
EMCDDA 2007: selected issue
Alcohol and tobacco 
Alcohol and tobacco use by under-15s has been found to 
correlate with subsequent use of illicit drugs, although the 
nature of the drugs–alcohol–tobacco relationship is complex 
and inextricably linked to other aspects of youth culture in 
each country, as well as to drug availability, social norms, 
fashions and the influence of the leisure industry. In 2003, 
ESPAD school surveys found that the prevalence of daily 
smoking by the age of 13 ranges from 7 % to 14 % in 
most European countries, but is higher in Germany (18 %) 
and Estonia (17 %) and lower in Turkey (3 %) and Greece 
(4 %) (1). In over half of the countries, the prevalence is 
higher in boys than in girls, but in 12 countries prevalence 
among girls equals or exceeds that among boys. 
The proportions of students that report having been drunk 
at the age of 13 or younger also varies substantially 
between countries. Figures for drunkenness by the age of 
13 or younger are highest in Denmark, Estonia, the United 
Kingdom and Finland (33–36 %) and lowest in Turkey 
and Cyprus (5 % and 7 % respectively). In the majority of 
countries, more boys than girls report having experienced 
drunkenness by the age of 13, but the rates are similar in 
boys and girls in Ireland, Malta, Austria, Finland, the United 
Kingdom and Norway.
Drug use
The illicit substance most commonly used by young people 
under 15 years is cannabis; use of inhalants (2) is higher than 
that of any illicit drug other than cannabis. Countries that 
record drug use data for younger age groups report strong 
increases in the ever-in-lifetime prevalence of cannabis use 
during the early teenage years — the phase in life when 
experimentation with drugs is most likely to occur. Differences 
between age groups are much greater than differences between 
the sexes. In all countries, a large increase in prevalence occurs 
between the ages of 11–12 and 15–16: in Greece this increase 
is twofold while in England it is 15-fold (Figure 2).
ESPAD school surveys reveal that the prevalence of first 
cannabis use by the age of 13 is 0–4 % in Bulgaria, Estonia, 
Greece, Italy, Latvia, Lithuania, Cyprus, Hungary, Malta, 
Poland, Portugal, Romania, Finland, Sweden, Norway and 
Turkey and 5 % – 8 % in all other countries except the United 
Kingdom, where the figure is 13 %. Since 1995, the largest 
increases in initiation to cannabis use at this young age 
(increases of 4 % or more) have occurred in newer Member 
States (the Czech Republic, Estonia, Slovenia and Slovakia) 
(Figure 3). Only the Netherlands and the United Kingdom 
report a decrease (of 1 %) in early cannabis use between 
1995 and 2003. In all other countries early cannabis use 
was either stable or showed a small upward trend (one or 
(1)  ESPAD data for Germany cover only six Länder and for Turkey only six cities.
(2)  Products that are commonly inhaled such as gas fuels (e.g. cigarette lighter fuel and bottled gas), aerosols (e.g. antiperspirants and pain-relief sprays), glues 
and solvents (e.g. contact adhesives and cleaning fluids) and amyl nitrate.
Figure 1: Distribution of frequency of cannabis use sessions 
(percentage) according to age at fi rst use among a French ESCAPAD 
sample of adolescents largely aged 17 years
NB:   Overall sample survey size is 6 438.
  Among the respondents, 80 % were aged 17 and 20 % were aged 18. 
Source:  Reitox French national report.
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Figure 2:   Ever-in-lifetime use of cannabis among very young people
in four EU Member States, according to age
(1)   Data for the United Kingdom cover only England. The oldest age group in 
this data are 15-year-olds.
NB:   Year of survey in brackets.
Source:  Reitox and ESPAD.
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two percentage points), mirroring the changes in prevalence 
in general during these years.
With regard to the use of inhalants, in countries that survey under-
15s there appears to be little or no increase in prevalence after 
the age of 11–12 years, unlike cannabis, which suggests that 
experimentation with inhalants may peak before the age of 15. 
Prevalence estimates for other types of drug use are 
considerably lower than those for cannabis and inhalants, 
as is the case among older school students. Ever-in-lifetime 
use of ecstasy, amphetamines, cocaine or heroin rarely rises 
above 2 % by the under-15s in the reported school surveys.
Drug-related consequences among 
very young people: under-15s entering 
treatment for drug use and other problems
Only a very small number of under-15s enter treatment 
because of use of illicit substances. In 2005, 17 EU Member 
States and Turkey reported around 3 300 clients under 
15 years old entering drug treatment, which represents 
around 1 % of all drug clients (3). In most European countries, 
less than 1 % of drug clients are under 15 years old and in 
seven countries the proportion is between 1 % and 2 %. 
Only Romania has a higher rate, with 3 % of drug clients 
under 15 years old, but total figures are low in this case. 
In general, reported figures are low. Several possible reasons 
for this can be proposed.
• Prevalence of drug use among very young people is 
generally low.
• Even if young people use drugs, drug use has not yet 
developed into problematic drug use.
• The availability of treatment centres targeted to very 
young people is low.
• Access to treatment is difficult, especially for marginalised 
groups.
• Some children with drug-use problems as well as other 
concomitant problems might be captured in social 
services registers although their drug problems remain 
unrecorded.
• Data regarding drug use among children may be 
under-reported for privacy and anonymity reasons.
Even taking into account the fact that the number of people 
treated for drug problems in this age group may be 
underestimated for several reasons, the European total is 
very small. However, this group is often highly problematic, 
as people in this category may be using drugs to cope with 
social and psychological problems (Cullen, 2006). 
Figure 3: Changes between 1995 and 2003 in recalled use of cannabis at or before the age of 13 (percentage points) as reported 
by 15- to 16-year-old school students
NB:    Caution is required regarding small percentages and changes: percentage changes are rounded off to the nearest percentage point.
  For Bulgaria and Cyprus, changes are calculated from 1999 to 2003 rather than 1995 to 2003.
Source:   ESPAD.
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(3) See Table TDI-27 in the 2007 statistical bulletin.
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Between 1999 and 2005, the number of under-15s reported 
entering drug treatment in Europe increased substantially 
(from around 1 000 to an estimated 3 300) (4). However, 
as this increase was largely due to a sharp rise in treatment 
demands in the United Kingdom, the data cannot be taken 
as an indication of an overall upward trend among this age 
group in Europe.
Most data on drug treatment clients under 15 years old 
concern outpatient treatment centres; therefore, the following 
description of their profile will focus on outpatient clients. 
The large majority of under-15s who enter treatment do so 
for primary cannabis use, and to a lesser extent for use of 
inhalants; only a very small proportion of young drug clients 
use opioids or other substances as their primary drug (5). 
Countries reporting a non-trivial number of clients under 
15 years old in treatment for drug use are Germany, Ireland, 
Spain, France, Italy and the United Kingdom; and Germany, 
Italy and the United Kingdom report some opioid users 
among clients under 15 years (6). The gender distribution 
among drug clients shows a higher proportion of girls in 
the youngest age group: there are 2.5 boys for every girl 
among clients under 15 years old, while among clients over 
19 years old the gender ratio is 4.1 to 1 (7). This might be 
related to several factors: the narrowing gap between males 
and females in social behaviours, including drug use; the fact 
that young girls may be introduced to drug use by an older 
male partner; the delayed psychosocial development among 
boys compared with girls; the role played by psychiatric 
co-morbidity or preceding disorders earlier in childhood. 
Research indicates that, at this age, gender differences in 
the prevalence of behavioural disorders such as attention 
deficit (hyperactivity) disorder (AD(H)D) or conduct disorders 
(CD) are less pronounced than gender differences in the 
prevalence of substance abuse (Fegert, 2006). However, 
because of the limited research that has been conducted 
in this area, the low figures reported in treatment and the 
methodological limitations in the drug treatment data, 
interpretations should be made with caution (8).
In 2006, an additional data collection on under-15s entering 
drug treatment was conducted in Bulgaria, Germany, 
Ireland, Latvia, Slovakia, the United Kingdom and Turkey (9). 
In these countries, a total of 2 739 children were reported to 
have entered treatment in 2005. Most cases occurred in the 
United Kingdom (80 %) and, to a lesser extent, in Germany 
(14 %); the other countries contributed with only few cases. 
The limited case numbers in the selected countries do not 
allow firm conclusions to be drawn.
Very young drug users enter treatment mainly following 
referral by court, family or social services. Social services 
play an important role in treatment referrals among the 
youngest clients, who may be subject to highly problematic 
family and social conditions and come into contact with other 
social or health services for reasons other than drug use 
(e.g. family and school problems, delinquency).
Other consequences of drug use, such as infectious 
diseases (10) and drug-related deaths, seem to be very rare 
in the youngest drug users, partly because of their short drug 
career. In 2005, 18 drug-related deaths among children 
under the age of 15 were reported, which represents 0.2 % 
of the total number of drug-related deaths in Europe (11). 
Although it is possible that some drug-related deaths in this 
age group are not reported as such, the low numbers, even 
in countries where it can be assumed that reporting of drug 
deaths is very thorough, support the general finding. 
High-risk groups and correlates 
Individual analyses conducted on several surveys, including 
school surveys, in a variety of countries have identified 
groups at high risk of early drug use and vulnerability 
factors that are correlated with higher levels of drug taking. 
Factors associated with drug use at an early age often 
co-occur; children at risk of early drug taking are frequently 
in a complex problematic condition, experiencing family, 
school and other social and psychological problems 
(Prinz et al., 2000). Some of the main vulnerability factors 
are reported below, along with possible effects of early 
drug use.
Family
Children whose parents or other family members use 
psychoactive substances are known to be at higher risk of early 
drug use because of problems in the social and psychological 
family functioning or because of the neurobiological 
consequences of maternal substance use during pregnancy on 
child development (Bancroft et al., 2004; Obot et al., 2001; 
Repetti et al., 2002). Alcohol use in the family is also strongly 
associated with a high risk of drug use among children 
(4) See Table TDI-30 (part i) in the 2007 statistical bulletin.
(5) See Table TDI-10 in the 2007 statistical bulletin.
(6) See Tables TDI-103 and TDI-122 in the 2007 statistical bulletin.
(7) See Table TDI-29 in the 2007 statistical bulletin.
(8)  See report on data coverage at http://www.emcdda.europa.eu/?nnodeid=1420
(9)  See Tables TDI-123, TDI-124 and TDI-125 in the 2007 statistical bulletin.
(10)  Data on the prevalence of drug-related infectious diseases are not available for this age group. 
(11) See Table DRD-1 in the 2007 statistical bulletin.
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(Clark et al., 2005). At European level, data available on the 
number of drug treatment clients living with children (alone 
or with a partner) indicate that a total of 27 908 outpatient 
and inpatient drug clients (14.3 % of all clients) live with their 
children; of these, 5 % live alone with one or more children. In 
some cases, children are living with more than one drug user. 
Research conducted in the United Kingdom found that at the age 
of 15, young people whose parents had used drugs during the 
previous year were more than twice as likely to have used drugs 
themselves than were those whose parents had not used drugs. 
Sibling drug users may also have a negative role on children’s 
behaviour: research in several countries reports that among 
children with drug-using siblings the rates of drug use are much 
higher than among children with siblings not using drugs. Being 
in a single-parent family (Denmark), parents not knowing where 
children are in the evening (Denmark, the Netherlands) and 
children going out every evening (Greece) are indicated as 
risk factors for or associated with early drug use. Children from 
families with low educational level, unemployment or precarious 
labour conditions and low affluence may have a higher risk 
of drug use (Prince’s Trust, 2004); however, a U-shaped curve 
shows that both high and low family incomes are related to high 
drug prevalence. Violence, sexual abuse, especially among 
girls, and criminal behaviour in families are other risk factors for 
early drug use (Fegert, 2006). 
School
Research carried out on the relation between school 
performance and early drug use has shown an association 
between the risk of drug use and early school leaving, school 
truancy, poor school performance and expulsion or exclusion 
from school. Data from the Scottish school survey show that 
56 % of children who have truanted school in the last year have 
tried drugs in the last year compared with 28 % of non-truants. 
The association seems to be even stronger for exclusion from 
school: 36 % of children who have been excluded from school 
have used drugs in the last 12 months compared with 8 % of 
children who have never been excluded.
Ethnic minorities and other socially excluded groups 
Though harmonised data are lacking at European level 
regarding the relation between drug use and membership 
of ethnic minority groups, some countries report a higher 
involvement in drug use among children from some 
ethnic minorities. In Italy, the prevalence of foreign drug 
users passing through the juvenile justice services, and of 
foreigners referred for drug-related crimes, is higher among 
the under-15s than among older age groups.
Children from socially and culturally marginalised or 
disadvantaged groups, for example from some Roma 
communities in Slovakia, are reported to start alcohol, 
tobacco and drug use at a very early age. Analysis of the 
2005 school survey for England found that pupils of mixed 
ethnicity were more likely than any other group to have taken 
drugs in the last year, and Asian pupils were least likely 
to have done so. A Home Office study (2001) found that 
homeless and street children have higher rates of drug use at 
an early age.
Youth offenders and children in care
Several research reports show an association between drug 
use and criminal activities or norm-breaking among very 
young people. Young people involved in crime and children 
in care have been indicated as high-risk groups for using 
drugs in some Member States (the Netherlands, the United 
Kingdom).
Co-morbidity, markers or predictors: 
the role of behavioural disorders
Attention defi cit (hyperactivity) disorder (AD(H)D) is estimated to 
affect 3–5 % of all children. Low neuronal activity in noradrenergic 
and dopamine pathways in specifi c brain areas explains patients’ 
pronounced diffi culties in fi ltering incoming (cognitive and emotional) 
stimuli for relevance and thus their inability to maintain attention, 
focus and affect regulation. Hyperactivity is an additional, but not 
essential, symptom. AD(H)D has very strong impact on an individual’s 
psychological development, education, relationships and family; 
however, the lack of specifi c instruments and direct markers makes 
it diffi cult to make a fi rm diagnosis. Professionals in some Member 
States object that AD(H)D should be considered not a disease entity 
per se, but rather a fi nal common behavioural pathway for 
a variety of emotional, psychological and/or learning problems. 
Furthermore, among the public the perception of recent increases in 
the prescription of amphetamine derivates such as methylphenidate 
has raised concerns. Pharmacotherapy with these stimulants 
normalises the neuronal systems for attention and focus and is part 
of — though not the only — standard treatment for AD(H)D. 
Proper diagnosis and pharmacotherapy are protective against the 
later development of drug problems, but the diversion of prescribed 
stimulants for non-medical use might be a growing problem 
(Poulin, 2007).
In ICD-10, conduct disorders (CD) are characterised by 
a repetitive and persistent pattern of dissocial, aggressive 
or defi ant conduct. Such behaviour, when at its most 
extreme for the individual, may amount to major violations of 
age-appropriate social expectations, and is therefore more severe 
than ordinary childish misbehaviour or adolescent rebelliousness. 
As it implies an enduring pattern of behaviour, isolated dissocial 
or criminal acts are not in themselves grounds for the diagnosis.
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Psychological problems: AD(H)D, 
conduct and mental disorders 
Children affected by attention deficit (hyperactivity) disorder 
(AD(H)D) and conduct disorder (CD) are increasingly 
reported as a high-risk group for drug use. Recently, this 
problem has attracted increasing attention (see box on 
co-morbidity). There is known correlation between drug use, 
especially cannabis use, and early forms of schizophrenia 
as well as other psychological disorders. Cannabis use 
is widespread among young psychiatric patients, and is 
interpreted by some as a type of inadequate self-medication 
(Witton, 2007).
Responses
Prevention
Responses in Member States to substance use among the 
very young vary on a continuum between predominantly 
universal approaches, i.e. the provision of classical 
prevention programmes (Griffin et al., 2003) in schools 
and communities without any risk assessment, and — at the 
other extreme — approaches to be implemented only when 
substance use is already suspected (early intervention). 
The former prevail in, for instance, Ireland and the Baltic 
States, the latter in France.
Most Member States report the use of risk-factor-led 
approaches in the middle of the continuum. These 
approaches aim to tailor prevention responses to the high-risk 
groups described in the preceding sections, i.e. families at 
risk through drug use, economic situation, members of certain 
ethnic groups, those with conduct and mental disorders and 
those living in deprived neighbourhoods (see Chapter 2 
in the 2007 annual report). 
The delivery of these interventions is mostly through existing 
social or health services or through ‘come structures’ 
(e.g. family and youth counselling centres in Germany, 
Greece and France). The effectiveness and, especially, 
the efficiency of these interventions has not been proven. 
Protocol-like detailed programmes that would allow scientific 
evaluation of contents, results and intensity of interventions 
are very rare in this field.
Global strategy responses
Some Member States already address the question of 
very young people in their drugs and other strategies by 
defining priority target groups and services to be delivered. 
For instance in Ireland, homeless young people receive 
comprehensive assessment in emergency care, specialised 
accommodation and family support provision. The Irish 
and United Kingdom (e.g. Every Child Matters) strategies 
focus on the harmonisation of child-related policy in areas 
such as early childhood care and education, youth justice, 
child welfare and protection, children and young people’s 
participation, research on children and young people and 
cross-cutting initiatives for children. It is argued that factors 
that contribute to disadvantage in general (McArdle et al., 
2006) — for example poverty, unemployment, drug and 
alcohol abuse, violence, inadequate and sub-standard 
housing — must be tackled in parallel with educational 
disadvantage per se and in an integrated way, along with 
a lifelong approach to mental health. 
The strategies propose early assessment of vulnerable 
children in key risk groups in primary care, care 
management and appointment of lead professionals for 
those who need support and intervention, and integrated 
information systems to help agencies work together to track 
interventions with individual children and young people. 
Generic services 
An important role in this field is played by prevention centres 
(Greece, Cyprus), youth welfare (Germany) or public health 
(Ireland, Cyprus, Hungary) agencies or teams whose task 
is to support parents in raising their children or to intervene 
when parents are no longer able to fulfil their parental duties. 
Weighing up the rights of the parents and welfare of the 
child, State authorities exercise restraint if parents do not 
agree with external intervention. In addition, school-based 
services (reported by 16 Member States as being regularly 
or frequently available) can detect, support and refer children 
with psychosocial, behavioural or academic problems, 
often according to established protocols. In Greece, juvenile 
protection associations operating in courts of first instance 
help adolescents who display antisocial behaviour or are in 
danger of becoming involved in crime because of an absent 
or inappropriate family environment or other unfavourable 
social conditions. An additional resource and conceptual 
leap for this approach seems to be the merging of addiction 
care with (child) mental healthcare, as in Germany and 
recently in the Netherlands. Especially with regard to young 
people, this trend to interweave addiction care and mental 
healthcare has the great advantage that addiction problems 
are now generally treated within a wider mental health and 
social context.
Despite the relatively high prevalence of inhalant use among 
under-15s, the dangers of inhalant/volatile substance abuse 
by young people in the EU have received far less attention 
than illicit drugs and alcohol. In the United Kingdom, 
a television advertising campaign launched in the 1990s 
and specifically aimed at volatile substance abuse was 
hailed a success following subsequent decreases in recorded 
deaths among young people. However, the success has been 
questioned as the decrease was also noted in regions where 
there had been no broadcasts (Orr and Shewan, 2006).
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Standardised programmes for selective 
and indicated prevention
High-risk families are not simply low-income families: one risk 
factor consistently mentioned in national studies (Denmark, 
the Netherlands, Sweden, the United Kingdom) 
is parents’ level of knowledge of their children’s whereabouts 
in their leisure time and about their friends.
Parenting is therefore a core component of prevention 
programme protocols, and some countries (Spain, Ireland, 
Romania, Norway) are implementing selective prevention 
programmes for families at risk, as well as parents in 
substitution treatment (Spain). These programmes focus on the 
development of educational skills, rule setting and parent–child 
relationships and are frequently evaluated with good results. 
Programme-based approaches to the parenting of children 
with behavioural problems are effective in compensating for 
part of the problem trajectory (Reyno and McGrath, 2006; 
Stephenson and Helme, 2006). In Galicia in Spain, evaluation 
of a programme for the teachers and parents of children 
between the ages of 8 and 10 with disruptive behavioural 
problems in the classroom (impulsiveness, aggressiveness, 
attention problems, hyperactivity) is under way. 
Several intervention programmes for children with diagnosed 
behavioural disorders have been published (Miller et al., 
2002; Thompson et al., 1997; Zonnevylle-Bender et al., 
2007). The Dutch prevention programme ‘Match’ targets 
children aged between 4 and 14 years who show risk factors 
such as early and persistent antisocial behaviour, alienation 
and rebelliousness. This programme matches a child at risk 
to a volunteer adult who has been trained to support the child 
during leisure activities within a relationship based on mutual 
trust. To participate in ‘Match’ it is required that the child at 
risk is not yet involved in an environment of heavy drug use.
Focus on AD(H)D
The recognition that attention deficit (hyperactivity) disorder 
(AD(H)D) and conduct disorder increases the risk of children 
developing a substance use disorder has prompted efforts in 
Member States such as Germany, the Netherlands, Slovakia 
and Sweden to improve and professionalise early detection 
in primary care and schools, to achieve proper diagnosis 
and to provide well-balanced treatment (between psycho-and 
pharmacotherapy) of these disorders. In the Netherlands, 
evidence-based multidisciplinary guidelines have been 
established to diagnose and treat AD(H)D among children 
and young people, and a specialised protocol has been 
established to screen for, diagnose and treat AD(H)D among 
clients in drug treatment. This reflects the concern in Europe 
about the increasing prescriptions for methylphenidate for 
children by non-specialists.
Treatment for very young people using drugs
Early intervention 
Generally, there is no comprehensive risk factor assessment that 
focuses on early detection of drug use. In some Member States 
(Germany, Greece, the Netherlands), specialised facilities 
offer counselling and care for children and teenagers with drug 
problems although coverage is limited. Many facilities combine 
inpatient and outpatient measures and include important 
elements from both addiction therapy and youth welfare. 
Treatment
Little information is available on drug treatment targeted to 
drug-using children. Although only one third of European 
countries report the existence of drug treatment centres for 
children or young people (Germany, Greece, Luxembourg, 
Cyprus, the Netherlands, Austria, Portugal, Romania), in most 
countries specific programmes or interventions for drug-using 
children are available. Treatment centres or programmes 
specifically targeted to child drug users are found in several 
settings: prevention centres or programmes (e.g. Cyprus, 
Austria); treatment services for adult drug users focusing 
on a specific substance (e.g. cannabis clinics in France, 
programmes on volatile substances in the United Kingdom); 
programmes for drug-using children in child psychiatric 
clinics (e.g. Hungary); or in institutions for problematic 
children, such as State care, reformatories, institutions for 
problematic or sentenced children (e.g. the United Kingdom). 
In the United Kingdom, a national framework has been 
developed to address volatile substance abuse.
Owing to scarce treatment availability, some children 
encountering problems related to drug use enter treatment in 
the general drug treatment services for the adult population. 
However, direct contact with adult drug users consuming 
heroin, cocaine and other drugs may have a negative 
influence on the behaviour of these children. For that reason, 
several countries have identified a need to establish drug 
services specifically for very young people.
The most common treatment approaches for drug-using 
children are based on individual care plans, in which health, 
social and educational services collaborate to produce 
an integrated intervention. Family involvement is another 
fundamental element in the treatment of children, and may 
include therapeutic sessions and social work with the family. 
Cognitive behavioural therapy and motivational support are 
common approaches in interventions for drug-using children. 
Legislation and regulations
It is known that use of tobacco and alcohol (age of onset, 
intensity of use, social perception and attitudes) has a major 
influence on initiation of illicit drugs use. In most Member 
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States, this connection is taken into account in public health 
policies. From this perspective, measures to prevent the 
early use of licit substances are viewed also as prevention 
against illicit use. Controlling the access of children and 
adolescents to licit psychoactive substances provides strong 
protection against the harm caused by these substances. This 
is particularly important in this group, as they are still in a 
phase of biological development when effects, e.g. on the 
neural system, could be more harmful than later. In addition, 
there is some evidence that delaying the onset of drug use 
leads to a reduction in any drug use at a later age. 
The main approach in this area is to allow purchase or 
consumption of tobacco or alcohol only after a certain age or 
to limit access to places of leisure-time activities (pubs, discos) 
by imposing age limits.
National legislation differs widely across the Member States, 
and numerous measures have been used in attempts to 
reduce alcohol-and tobacco-related problems among very 
young people. For instance, some countries prohibit the 
employment of minors in some jobs that deal with alcohol or 
tobacco. This is the case in Estonia and Latvia. In Estonia, 
adults are also prohibited from buying tobacco and alcoholic 
beverages and offering them to minors. Estonia also reports 
that minors do not have the right to send or receive alcoholic 
beverages in postal consignments. 
However, the most common strategy reported by Member 
States is the setting of a legal minimum age for purchase or 
consumption. Other legal measures targeting young people 
reported by Member States include a ban or restriction 
of purchase or consumption in specific public places, an 
increase in taxes related to these substances and restrictions 
on the advertising of such products. 
Age requirements and other restrictions for purchase 
and consumption of alcoholic beverages or tobacco
Only Cyprus reports any specific legislative instruments or 
regulations specifically targeting minors under 15 years 
concerning the consumption or purchase of alcohol and 
tobacco, although even there the laws exhibit discrepancies, 
the age limit on the purchase of alcoholic drinks being 
variously specified as 14, 17 or 18 years. 
In Europe overall, the age limit for buying or consuming 
alcoholic beverages varies from 14 to 20 years and that for 
buying or consuming tobacco products ranges from 16 to 
18 years. However, there are sometimes exceptions even 
within the same country. Greece, for example, reports a 
different age limit for on-premises sales than for off-premises 
sales: the legal age for drinking alcoholic beverages on 
premises of direct consumption is 17 years, while there 
are no age restrictions on off-premises drinking or on the 
purchase of alcohol. In Sweden, the legal age for buying 
low-strength beer (in the 2.25–3.5 % alcohol range — the 
strongest alcoholic beverage sold outside the retail monopoly 
in Sweden) is 18 years but the age limit for buying alcohol at 
monopoly stores is 20 years.
In some countries, age limits differ for different beverages. 
For example, in Germany and the Netherlands, the age limit 
for the purchase of mild alcoholic drinks such as beer is 
16 whereas for stronger alcoholic drinks such as wine and 
spirits it is 18. In contrast, the Czech Republic, for instance, 
does not distinguish between different beverages and the 
legal age for the purchase of any alcoholic beverage and 
tobacco products is 18 years.
In the Czech Republic, Estonia, France, Hungary, the 
Netherlands and Portugal, retailers may ask for proof of 
age. In Hungary, for example, if evidence of the buyer’s 
age is inadequate, the sale of tobacco products or alcoholic 
beverages must be denied. In France, decree No 949 of 
6 September 2004 states that the vendor has the right to ask 
for a form of identity to prevent the sale of tobacco to minors 
under the age of 16. In Sweden, by comparison, staff must 
ask anyone who looks younger than 25 to show proof of 
age at the stores of the Swedish alcohol retailing monopoly 
(Systembolaget). 
In addition to checking the age of the buyer, in places 
where tobacco products are sold in the Czech Republic, the 
retailer is obliged to place a clearly visible sign stating that 
these products cannot be sold to persons under 18 years. 
Also in the Czech Republic, it is forbidden to place vending 
machines selling tobacco products or alcohol in places 
where it is not possible to restrict their sale to persons over 
18 years. In Romania, Law 125/2001 forbids the sale 
to minors of alcohol and tobacco products in automatic 
vending machines. 
In several Member States, nationwide provisions may be 
enhanced by more stringent regulation at regional and/or 
local level. In the Czech Republic, other restrictions on 
the sales, serving and consumption of alcohol can be laid 
down by an ordinance issued by a municipality with its 
own powers. In Slovakia, the State retail inspectorate is 
responsible for supervising the enforcement of the ban 
on the sale of tobacco and alcohol to young people under 
the age of 18. 
In the Czech Republic, responsibility for the implementation 
of these restrictions lies with the municipal police and 
a municipality with delegated powers. This is also the case 
in Sweden, where local authorities and the police are in 
charge of monitoring compliance with legislation on the sale 
of tobacco and alcohol. In the Netherlands, compliance 
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with the tobacco law by youngsters aged 13–15 is assessed 
regularly. 
In Sweden, for example, staff found selling alcohol and 
tobacco to minors can be fined or sent to prison for 
a maximum of six months and the owner may also be 
prohibited, under penalty of a fine, from selling tobacco 
or beer for a given period of time. In the Czech Republic, 
failure to implement the ban on sales of tobacco and alcohol 
is punishable by a fine of between CZK 50 000 in the case 
of a physical entity and CZK 500 000 in the case a legal 
entity (12). In Portugal, the sale of tobacco or alcohol to young 
people (under 16) is an administrative offence punishable by 
a fine, with the illegal sale of tobacco subject to a fine of 
EUR 1 900 to EUR 3 740 (for an individual) and 
EUR 30 000 to EUR 44 000 (for a company) and 
corresponding fines of EUR 498–30 740 and EUR 2 493–
29 927 for the illegal sale of alcohol. In Cyprus, the supply of 
tobacco to a person under 18 constitutes a criminal offence (13). 
In Latvia, a person inducing a child to use alcoholic 
beverages or to smoke shall be held liable as prescribed 
by the law, and the giving of such products to minors is 
considered as inducing the child to use them and will be 
punished the same way. 
The protected zone
Besides setting minimum legal age limits for the purchase and 
consumption of alcoholic beverages and tobacco, in most 
countries regulations ban or restrict smoking or drinking, 
or sometimes purchasing, alcoholic beverages in major 
public places such as educational facilities (e.g. in canteens, 
bars and restaurants in Portuguese schools) or during sports 
events (alcohol in France, alcohol and tobacco in the Czech 
Republic) often frequented by the young. 
In Hungary, advertising of alcoholic beverages is prohibited 
in institutions of public education, in health institutions and 
within a distance of 200 metres from their entrance 
(Act LVIII of 1997 on business advertising activity). 
Romanian legislation (Law No 148/2000) prohibits the 
advertisement of alcohol in youth publications, learning 
units and public halls. 
Regarding the legal provisions in national legislation that 
address minors as users, Member States fall into two main 
groups: those where very young people do not appear in 
court and those where they do. 
Increase in taxes
Member States (14) also use tax increases to reduce the 
attractiveness of tobacco or alcohol consumption. For 
example, in Luxembourg, the government has raised 
an additional tax on the designer drink market, which 
particularly targets youngsters, and in France tax penalties 
are levied on pre-mixed alcoholic beverages specifically 
designed for the young. In Germany in 2004, a tax was 
imposed on tobacco and the price of ‘alcopops’ was 
increased by about 80 cents in order to render these 
products financially less attractive to young people. 
(12)  In the Czech Republic, the sale, serving or any manner of facilitation of the consumption of alcohol to a person aged under 18 can also be prosecuted 
according to 200/1990 Coll. on Misdemeanours (punishable with a fine of up to CZK 3 000 or up to CZK 5 000 and prohibition of activities for up to one 
year).
(13)  This provision is included in both the protection of health law and the law on children, for minors under the age of 14.
(14)  The communication from the Commission on ‘An EU strategy to support Member States in reducing alcohol-related harm’ (COM (2006) 625 final, 
24.10.2006) reports that Denmark, Germany, Ireland, France and Luxembourg have imposed a special tax or compulsory labelling for products such as 
‘alcopops’. 
European Union action on use of tobacco and alcohol 
by very young people
The European Union has competence and responsibility to 
address public health problems such as harmful and hazardous 
alcohol and tobacco use by complementing national actions in 
this fi eld, as stated in Article 152 of the EC Treaty. 
In 2001, the Council adopted a recommendation on the 
drinking of alcohol by young people, in particular children 
and adolescents, which invites the Commission to follow up, 
assess and monitor developments and the measures taken, 
and to report on the need for further actions. In its conclusions 
of 5 June 2001, the Council invited the Commission to put 
forward proposals for a comprehensive Community strategy 
aimed at reducing alcohol-related harm to complement 
national policies. The Council conclusions on alcohol and 
young people of June 2004 reiterated this invitation. Most 
Member States have taken actions to reduce alcohol-related 
harm, and many of them have extensive policies in this fi eld. 
Concerning tobacco, in December 2002, the Council 
adopted a recommendation on the prevention of smoking 
and on initiatives to improve tobacco control with the aim of 
encouraging Member States to improve tobacco control with 
particular emphasis on stepping up the prevention of smoking 
among children and adolescents. 
Besides this non-binding legal instrument, the European 
Parliament and the Council also adopted, in May 2003, 
a directive intended to prohibit tobacco advertising at EU 
level. The directive is founded not on the article related to 
public health (Article 152) but on the article related to the 
internal market. 
In addition to legislative action, two anti-tobacco campaigns 
in the media have also aimed at highlighting the hazards 
of passive smoking and at promoting tobacco-free lifestyles, 
particularly among young people.
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Illicit substances
A first analysis was made in October 2003 on the legal 
provisions in national legislations that address the issue of 
drugs among very young people (15). The objective here is to 
examine recent changes in legal approaches regarding drug 
use among minors. 
Almost all drug action plans or strategies of Member States 
target young people in prevention, and in some cases also 
in treatment provisions (EMCDDA, 2006). In addition, 
some countries, such as Portugal, report specific provisions 
in their strategic document directed at very young people. 
Some countries have also provided interesting information 
related to the situation in which the minor is the ‘victim’, i.e. 
when exposed to drugs by an adult. In the Czech Republic, 
for example, the penal code protects minors against illicit 
drugs and allows for stricter sanctions if the drug offence was 
committed against a person aged under 15 or 18. Similarly, 
in the Czech Republic and Estonia (2004 national report), 
inciting or promoting the use of illicit drugs by young people 
attracts a high penalty. In Slovakia, any incitement to abuse 
any addictive substance constitutes a criminal offence. 
The sale of illicit drugs around schools or locations usually 
attended by young people is also punished severely. This is the 
case, for example, in Denmark, where an amendment to the 
Euphoriants Act in 2004 deems it a significantly aggravating 
circumstance if drugs are sold or offered free of charge with 
the view to subsequent sale in restaurants, discotheques or 
similar places typically attended by children or young people. 
In England and Wales, two pieces of legislation affect the 
availability of inhalants to young people. The first of these is the 
Intoxicating Substances (Supply) Act 1985. This makes it illegal 
for retailers to sell volatile substances to anyone under the age of 
18 if there is reason to believe that they will use it for inhalation 
and intoxication purposes. This legislation does not, however, 
specify which products should be restricted and few cases have 
been brought to court. In 1999, the supply or sale of cigarette 
lighter refills to people under the age of 18 was specifically 
banned under the Cigarette Lighter Refills (Safety) Regulations. 
Measures to restrict availability are also in place in Scotland 
and further legislation in the United Kingdom addresses solvent 
availability for all ages. In recent years, the British Aerosol 
Manufacturers’ Association (BAMA) has promoted the use 
of a warning on many commonly abused products (Orr and 
Shewan, 2006). In Romania, prison sentences were increased 
in 2005 for offences related to the supply of a toxic chemical 
inhalant to a minor to use for intoxication purposes. 
In Cyprus, under the Child and Family Programme offered by 
the social welfare services, drug offenders under the age of 
14, not involved in a serious crime, do not appear in court 
and their case is managed by the social welfare services. 
Similarly, in Denmark, it is not the courts which decide the 
outcome for very young drug offenders. The municipality is 
responsible for examining the case and taking into account 
the overall social support being provided, as well as for 
drawing up an action plan for the entire intervention process, 
including treatment for drug use. In special cases (young 
people under 18 who have serious social and behavioural 
problems due to drug abuse), the county is obliged to offer 
drug addiction treatment. In Hungary, juvenile offences 
committed by children under 14 years cannot be punished 
and the child welfare services and the court of guardians are 
notified by the investigating authority immediately. 
In the Member States which reported that very young people 
appear in court, there is very often a strong bias towards 
educational or treatment measures. 
In the Czech Republic, for instance, children under 
15 years are not criminally responsible and a special court 
for juveniles may impose either supervision by a probation 
officer, a therapeutic, psychological or other suitable 
educational programme in an educational care centre, or 
protective education. 
The diversion of young offenders from prosecution is also 
a key element in Ireland and Greece. In Ireland, under 
the Children Act 2001, judges are required to seek 
pre-sentencing reports from the Probation and Welfare 
Service in all cases involving under-18-year-olds where the 
judge is considering a custodial sentence or community 
sanction. In Greece, offenders aged 8–13 years are 
not prosecuted but instead are subject to reformatory or 
therapeutic measures. Once the minor enters his/her 14th 
year, the court can impose imprisonment in a special prison 
for young persons (Law 3189/2003). Therapeutic measures 
are imposed if the minor uses drugs, following a psychiatric 
report and laboratory results. 
In Luxembourg, the public prosecutor decides whether to 
close or to prosecute a drug-related case involving a minor. 
A minor can be prescribed compulsory treatment before 
his or her case is brought to court. On the other hand, the 
juvenile court can order educational assistance, out-of-home 
placements, treatment or social work supervised by the 
central service for social assistance. Médecins sans frontiers’ 
(15) http://eldd.emcdda.europa.eu/?nnodeid=5175
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youth solidarity project works closely with the juvenile court 
to care for young drug law offenders. 
In Slovakia, the new penal law (16) incorporates special 
provisions for minors, which cannot be used for a person 
older than 18 (depending, for example, on the severity of the 
act, imposition of penalties, probation upon sentencing).
In the same way in Spain, Organic Law 5/2000, 
12 January, regulates the criminal liability of minors. Juvenile 
courts assume the responsibility of passing judgment, and 
minors aged 14–18 shall be criminally liable when they have 
committed crimes or offences considered as such in the penal 
code. However, for the youngest drug offender, should the 
need arise, therapeutic measures laid down in the law can 
be applied. 
Conclusions
While the majority of under-15s have not used licit or illicit 
substances, and substance dependence is very rare in 
this age group, use at a very early age is recognised as a 
predictor of later drug dependence and other problems and 
as an indicator and crucial element of a difficult family and 
social situation for those concerned.
The prevalence of daily tobacco smoking at the age of 
13 varies in European countries from 7 % to 14 % and for 
having been drunk from 5 % to 36 %. The prevalence of 
illicit drug use at that age is lower. In almost all European 
countries, lifetime prevalence of cannabis use among 
under-15s is between 0 % and 8 %, though in the United 
Kingdom it rises to 13 %. Most countries report either a 
stable or an increasing prevalence of cannabis use among 
very young people. The prevalence of the use of inhalants is 
lower, and for other substances lower still.
Problematic drug use is rarely found among very young 
people; in Europe only 1 % of treatment clients are younger 
than 15. While the numbers involved are low (about 4 000 
in 2005), a sizable increase in very young clients entering 
treatment for drug use is reported from 1999 to 2005. An 
increase in the numbers of young people entering treatment 
is in itself a reason for the establishment of drug treatment 
services specifically for children, and that could result in 
further increases in the numbers of children in drug treatment. 
Often children enter drug treatment referred by families and 
by social services or by the criminal justice system; 
the primary drugs are mainly cannabis or inhalants; only in 
a few cases are opioids the primary drug. The proportion of 
girls among the very young client group is higher than in the 
older age group. Possible reasons include a greater similarity 
of behaviour in boys and girls in this age group or a more 
equal gender distribution of co-morbid disorders at this age 
or delayed psychosocial development of boys compared 
with girls.
The few regular drug users among very young people are 
often part of a highly problematic group of the population, 
in which drugs are just one among other factors. Child drug 
users often come from problematic families and socially 
excluded groups; a negative relationship with school also 
seems to be associated with a high risk of drug taking among 
children. Increasing attention is currently being paid 
to the relation between AD(H)D, conduct disorders 
and other psychological disorders and drug use among very 
young people.
Responses targeted at child drug users mainly focus on 
prevention strategies, ranging from universal approaches to 
early intervention when substance use is already suspected. 
More attention has recently been given to the treatment 
of behavioural disorders in a global way. European and 
national legislation on substance use among young people 
focuses on restrictions on the purchase of licit substances 
(tobacco and alcohol) and on social interventions in the 
case of drug-using children committing crimes. In countries 
where children committing crimes are sent to court, treatment 
is often proposed as an alternative to punishment. Many of 
the children entering drug treatment are referred to it by the 
criminal justice system. Specialised treatment for drug-using 
children is still rare, but more targeted structures have been 
created recently, allowing better responses to the specific 
needs of very young people.
In general, interventions for children tend to focus not on drug 
use, but on a broader perspective in which the social context, 
in particular family and school, is a fundamental component. 
Preference is also given to integrated approaches in which 
drug treatment is coordinated with health, education and 
social services; the justice system may also be involved in 
ensuring compliance. The interventions aim to prevent an 
early initiation to substance use, which might lead to later 
regular use, or target a risk group within the population, 
tackling drug problems together with other problems.
(16)  The new Slovak penal code reduced the age of criminal responsibility by one year, meaning that a person having reached the 14th year of his/her age and 
not having exceeded the 18th year is considered as a juvenile. 
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